CytoSorbents

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

BZ_briefs

Equities

News

Small Cap

Movers

CTSO

CytoSorbents is progressing with U.S. FDA and Health Canada reviews for its DrugSorb-ATR device.

Health Care Equipment Supplier CytoSorbents Shares Dip Despite Projected Revenue Growth

vaccine-4892048

CytoSorbents shares are trading higher by 20% during Tuesday&#39;s session. The company entered into a new $20 million credit facility with Avenue Capital Group.

Why CytoSorbents (CTSO) Stock Is Trading Higher

Earnings

Penny Stocks

Eurozone

Commodities

Global

Intraday Update

Markets

Trading Ideas

BJDX

CING

DOYU

MBOT

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday.

The Dow traded up 0.27% to 37,758.26 while the NASDAQ rose 0.17% to 15,124.90. The S&amp;P 500 also rose, gaining, 0.23% to 4,792.56.

Gold Moves Lower; US Crude Stocks Decline Last Week

CytoSorbents Corp

Press Releases

CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India

CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference

Financing

CytoSorbents Announces Rights Offering

Health Care

CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

CytoSorbents Rights Offering Begins

CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue

General

CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai

CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering

CytoSorbents Further Strengthens Balance Sheet with Exercise of Previously Announced Series A Right Warrants

CytoSorbents to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

D. Boral Capital

HC Wainwright & Co.

EF Hutton

B. Riley Securities

Comments

CytoSorbents

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga